GeneDx’s Q1 2026 report did more than cut guidance and trigger class actions. It forced investors to rethink what the Fabric Genomics deal really added once a very large impairment charge and weaker reimbursement trends were on the table. For GeneDx shareholders, the loss over the past year was 50.1%, including dividends. If you had bought in on 30 October 2025, how much of that risk was already visible in the story you were reading?
This theme extends beyond GeneDx. See which of 33 healthcare AI stocks may still merit a closer look.
The Two GeneDx Stories Investors Had In Front Of Them
The shares cost US$132 at the start of the period, and anyone looking at GeneDx then was really choosing between two very different scripts for the same business.
The bullish Narrative pointed to a Fair Value of US$157, a notional price implied by its own assumptions, built on genomics and AI integration driving 23.9% revenue growth and profit margins rising toward 18.8% as Fabric Genomics folded in.
The more cautious Narrative put Fair Value at US$124 and treated expansion into general pediatrics as real but slower burning, with 19.7% growth weighed against reimbursement and competition risks.
What The GeneDx Results Put To The Test
GeneDx’s later filings showed Q2 2026 revenue of US$114.44m versus US$102.69m in Q2 2025, which backed both narratives on top line expansion. Profit told a different story. Net margin moved from 10.5% in Q2 2025 to a loss margin of 15.5% in Q2 2026, so the profitability jump in the bullish script remained unproven and the cautious case on risk looked better supported.
The hinge assumption was not demand; it was quality of earnings. When you assess another high growth healthcare stock, track whether rising sales are matched by a stable or improving net margin rather than relying on volume stories alone.
What GeneDx’s Drop Now Asks You To Believe
GeneDx trades at US$69.06 today, after a 50.1% fall over the past year. The selected Narrative argues that its Fair Value sits above the current price, hinging less on test volume and more on whether collections and reimbursement can support durable cash generation.
For that slide to look like an opening rather than a warning, a buyer today would need to believe GeneDx can materially lift outpatient genome collection rates while managing reimbursement pressure and legal costs without eroding future earnings power.
"The main thing that has to go right is GeneDx Holdings successfully lifting outpatient collection rates toward industry-standard levels, while expanding payer coverage and using AI-driven revenue cycle tools, so that strong exome and genome test volumes translate into sustained, profitable cash generation."
One Narrative disagrees with today's price. → See where this Narrative says GeneDx should trade
How Could You Get There Earlier?
This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.
- Company 1 - 23% below our estimate - serves hyperscale data center builders across power, cooling and connectivity technologies.
- Company 2 - 48% below our estimate - co-designs intricate chips and systems so demanding AI and industrial workloads run reliably.
- Company 3 - 38% below our estimate - applies AI and tighter carrier screening to reduce fraud and streamline insurance claims handling.
Those are three of them. See every one of the 36 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com